We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+30.01%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$358M
Cap. Flow
-$161M
Cap. Flow %
-5.18%
Top 10 Hldgs %
35.61%
Holding
108
New
34
Increased
17
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$63.9M
2
MRK icon
Merck
MRK
+$61.9M
3
CI icon
Cigna
CI
+$60.7M
4
CGON icon
CG Oncology
CGON
+$59.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$53.3M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$81.9M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$65.2M
3
IMGN
Immunogen Inc
IMGN
+$54.2M
4
BHVN icon
Biohaven
BHVN
+$53.1M
5
ZTS icon
Zoetis
ZTS
+$47.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
26
CALL
Cytokinetics
CYTK
$10.8B
$42.1M 1.36%
+600,000
New +$46.4M
ITCI
27
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$41.5M 1.34%
600,000
-110,000
-15% -$7.56M
ABBV icon
28
AbbVie
ABBV
$465B
$41.3M 1.33%
227,000
-57,405
-20% -$9.89M
BPMC
29
DELISTED
Blueprint Medicines
BPMC
$40.4M 1.3%
426,000
-189,000
-31% -$16.2M
LEGN icon
30
Legend Biotech
LEGN
$3.68B
$37.5M 1.21%
668,300
-16,700
-2% -$1.01M
GPCR icon
31
Structure Therapeutics
GPCR
$3.4B
$37M 1.19%
864,000
-216,000
-20% -$9.11M
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$38.5B
$36.3M 1.17%
+243,000
New +$40.5M
DHR icon
33
Danaher
DHR
$140B
$35.9M 1.16%
143,800
-146,200
-50% -$35.7M
IDYA icon
34
IDEAYA Biosciences
IDYA
$3.48B
$35.1M 1.13%
799,700
-720,300
-47% -$31M
AXSM icon
35
Axsome Therapeutics
AXSM
$12.1B
$34.4M 1.11%
431,000
-28,400
-6% -$2.38M
XENE icon
36
Xenon Pharmaceuticals
XENE
$6.28B
$30.6M 0.99%
710,000
-105,993
-13% -$4.88M
LNTH icon
37
Lantheus
LNTH
$6.68B
$29.9M 0.96%
480,000
+100,000
+26% +$5.88M
CRBU icon
38
Caribou Biosciences
CRBU
$148M
$29.7M 0.96%
5,785,352
-574,860
-9% -$3.54M
MIRM icon
39
Mirum Pharmaceuticals
MIRM
$6.84B
$28.7M 0.93%
1,142,850
– –
RCKT icon
40
Rocket Pharmaceuticals
RCKT
$342M
$27.6M 0.89%
1,025,000
-694,103
-40% -$19.7M
RGNX icon
41
Regenxbio
RGNX
$614M
$27.4M 0.88%
+1,300,064
New +$23.1M
APGE icon
42
Apogee Therapeutics
APGE
$10.1B
$25.6M 0.82%
+384,893
New +$16.8M
NMRA icon
43
Neumora Therapeutics
NMRA
$309M
$24.8M 0.8%
1,800,000
-190,632
-10% -$3.08M
DXCM icon
44
DexCom
DXCM
$28.9B
$24.5M 0.79%
+176,900
New +$22.2M
NGNE icon
45
Neurogene
NGNE
$660M
$23.7M 0.76%
465,237
-1,006
-0.2% -$33.6K
JSPR icon
46
Jasper Therapeutics
JSPR
$21.2M
$22.3M 0.72%
+760,000
New +$13.5M
IMNM icon
47
Immunome
IMNM
$2.63B
$21.6M 0.7%
873,891
-459,588
-34% -$9.33M
TMO icon
48
Thermo Fisher Scientific
TMO
$214B
$21.3M 0.69%
36,600
-146,000
-80% -$81.9M
GKOS icon
49
Glaukos
GKOS
$8.89B
$21.1M 0.68%
+224,000
New +$20M
RVMD icon
50
Revolution Medicines
RVMD
$39.1B
$20.5M 0.66%
635,000
+575,000
+958% +$17M
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2024 Portfolio in Review

As of Q1 2024, Avidity Partners Management held 108 positions worth $3.1B, up 13% from $2.74B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Avidity Partners Management withdrew a net $161M in Q1 2024, closing 18 positions and reducing 30 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $65.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 95% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Illumina worth $63.7M.

  • Avidity Partners Management's largest Q1 2024 buy was Illumina: 477,095 shares worth $63.7M.
  • Avidity Partners Management added most to Intuitive Surgical in Q1 2024, an estimated $53.3M increase.
  • Avidity Partners Management's biggest Q1 2024 reduction was Thermo Fisher Scientific, cutting an estimated $81.9M.
  • Avidity Partners Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $65.2M.
  • Avidity Partners Management's ten largest holdings make up 36% of its $3.1B portfolio in Q1 2024.
  • Avidity Partners Management opened 34 new positions and closed 18 in Q1 2024.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $3.1B.

Based on Avidity Partners Management's 13F filing for Q1 2024, filed 15 May 2024.